Browsing Cancer Therapeutics by author "Preece, Natasha"
Now showing items 1-2 of 2
-
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.
Girotti, MR; Lopes, F; Preece, N; Niculescu-Duvaz, D; Zambon, A; et al. (CELL PRESS, 2015-01-12)BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs. Resistance is often mediated by pathway ... -
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
Bridgeman, VL; Wan, E; Foo, S; Nathan, MR; Welti, JC; et al. (AMER ASSOC CANCER RESEARCH, 2016-01-01)Sunitinib and pazopanib are antiangiogenic tyrosine kinase inhibitors (TKI) used to treat metastatic renal cell carcinoma (RCC). However, the ability of these drugs to extend progression-free and overall survival in this ...